Recent Updates
Recently added Catalysts
DXCM Positive Sentiment

Dexcom Appoints Glenn Boehnlein to Board of Directors

Thursday, September 10, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Dexcom, Inc. has appointed Glenn Boehnlein to its Board of Directors, effective September 10, 2026. Boehnlein is a seasoned healthcare executive with over 20 years of experience in the medical technology sector. His previous role was as Vice President and CFO of Stryker Corporation, which enhances his qualifications for the board.

Market Sentiment Analysis

POSITIVE FACTORS

  • Appointment of a seasoned executive to the board.
  • Glenn Boehnlein brings over 20 years of experience.
  • His background in finance will benefit Dexcom.

Full Press Release Details

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Glenn Boehnlein to its Board of Directors, effective September 10, 2026. Mr. Boehnlein is a highly accomplished healthcare executive and finance leader with more than 20 years of experience in the medical technology industry. Most recently, he served as Vice President and Chief Financial Officer of Stryker Corporation, one of the world’s leading medical technology

Frequently Asked Questions

Who is Glenn Boehnlein?

Glenn Boehnlein is a healthcare executive with over 20 years of experience.

When will Glenn Boehnlein join the board?

He will join the Board of Directors on September 10, 2026.

What was Boehnlein's previous position?

He served as Vice President and CFO of Stryker Corporation.

What is Dexcom known for?

Dexcom is a global leader in glucose biosensing technology.

ShareAdd on Google
Tags: DXCM Viatris Investor Conferences Healthcare Dexcom Glenn Boehnlein medical technology Stryker Corporation Board of Directors
Last updated: Sep 10, 2026

Biotech snapshot

Cash runway
$2084M liquidity · $0M/mo burn
Low dilution risk
Lead asset
Basal insulinPhase 1
Type 2 Diabetes →